CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
治疗急性髓系白血病的异基因双阴性 T 细胞疗法
英文原题：Allogeneic double-negative T-cell therapy for acute myeloid leukemia.
查看英文原题
Allogeneic double-negative T-cell therapy for acute myeloid leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CD3⁺CD4⁻CD8⁻双阴性T细胞（DNT）是具有独特特征的T淋巴细胞亚群，对急性髓系白血病（AML）具有强效细胞毒性。重要的是，异体DNT不会引起移植物抗宿主病，并具备适合现货型细胞治疗的特性；早期临床试验已显示出有前景的疗效。DNT治疗可与传统AML疗法协同作用，也可通过嵌合抗原受体（CAR）进行转导。值得注意的是，在获得长期缓解的患者中，持续存在的CAR⁺ T细胞主要呈DNT表型。异体DNT独特且多样的治疗特性，使其成为AML过继细胞治疗的有力候选方案。
展开英文摘要原文
CD3 + CD4 - CD8 - double-negative T cells (DNTs) represent a unique subset of T lymphocytes with potent cytotoxicity against acute myeloid leukemia (AML).
Importantly, allogeneic DNTs do not induce graft-versus-host disease and have demonstrated characteristics suitable for off-the-shelf cellular therapy with promising efficacy in early-stage clinical trials. DNT therapy can synergize with conventional AML treatments and can be transduced with chimeric antigen receptors (CARs).
Notably, persistent CAR + T cells in patients, who achieved long-term remission, predominantly have a DNT phenotype. The unique and versatile therapeutic properties of allogeneic DNTs position them as a strong candidate among adoptive cellular therapies for AML.
论文信息
- 作者
- Tin E、Lee J、Zhang L
- 第一作者单位
- Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.Canada
- 通讯作者单位
- Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Department of Immunology, University of Toronto, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address: li.zhang@uhnresearch.ca.Canada
- 文献类型
- 综述
- 期刊
- Current opinion in pharmacology2025 Aug
- 原文标识
- PubMed 40441065 · DOI 10.1016/j.coph.2025.102537